Plant Name: Cornus officinalis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GRM1; GRM5; GRM3; GRM2; GRM8; GRM4; | |
| FFAR1; FFAR4; DRD4; ADORA3; GPBAR1; | |
| TSHR; NPSR1; CXCR1; | |
| AMY1A;AMY1B;AMY1C; PLA2G1B; TDP1; BLM; ALPI; RECQL; P4HB; PIK3R1; GLO1; HPGD; HSD11B1; MPO; AKR1B1; HSD17B10; ALOX15; ALDH1A1; HSD17B2; GFER; ALOX12; AKR1B10; NOX4; USP2; PYGL; POLB; | |
| PTPN1; CDC25B; PTPN2; PTPRF; ACP1; | |
| ACHE; GAA; BCHE; | |
| GRIK2; GRIA4; GRIA2; GRIK3; GRIK5; GRIK1; | |
| MET; CAMK2B; NEK6; CSNK2A1; AKT1; DAPK1; FLT3; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; AXL; NEK2; KDR; PKN1; | |
| CA12; CA5B; CA3; CA14; CA7; CA1; CA9; CA4; CA6; CA2; CA5A; | |
| NR1H4; | |
| PPARA; PPARG; PPARD; | |
| RORC; | |
| ESR2; | |
| HMGCR; MAOA; ALOX5; XDH; | |
| KDM4E; | |
| F10; PLG; | |
| MMP3; MMP2; MMP9; MMP13; MMP1; | |
| BACE1; | |
| TLR2; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| FUT7; | |
| ABCC1; ABCG2; | |
| SLC1A1; | |
| LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | AMY1A;AMY1B;AMY1C | Salivary alpha-amylase | P04745 | CHEMBL2478 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Ionotropic glutamate receptor | GRIK2 | Glutamate receptor ionotropic kainate 2 | Q13002 | CHEMBL3683 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | HMGCR | HMG-CoA reductase | P04035 | CHEMBL402 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| Serine protease | PLG | Plasminogen | P00747 | CHEMBL1801 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM5 | Metabotropic glutamate receptor 5 | P41594 | CHEMBL3227 |
| Small molecule receptor (family C GPCR) | GRM3 | Metabotropic glutamate receptor 3 | Q14832 | CHEMBL2888 |
| Small molecule receptor (family C GPCR) | GRM2 | Metabotropic glutamate receptor 2 | Q14416 | CHEMBL5137 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Small molecule receptor (family C GPCR) | GRM4 | Metabotropic glutamate receptor 4 | Q14833 | CHEMBL2736 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.777E-11 | 1.061E-08 | ALPI, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR2, GLO1, MMP1, MMP13, MMP2, MMP3, MMP9, NR1H4, PPARA, PPARD, PPARG, PTPN1, RORC, TP53 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.111E-10 | 3.456E-08 | ADORA3, ALK, AXL, CXCR1, DRD4, ESR2, FFAR1, FFAR4, FLT3, GPBAR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HPGD, IGF1R, KDR, MET, NPSR1, NR1H4, PPARA, PPARD, PPARG, PTPRF, RORC, TLR2, TSHR |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.191E-10 | 3.617E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0051966; regulation of synaptic transmission, glutamatergic | 2.025E-10 | 5.654E-08 | GRIK1, GRIK2, GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.923E-10 | 1.449E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.550E-10 | 2.024E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C8, CYP2D6, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.044E-09 | 2.320E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C8, CYP2D6, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 2.089E-09 | 4.099E-07 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 3.546E-09 | 6.381E-07 | ADORA3, ALK, AXL, CXCR1, DRD4, FFAR1, FFAR4, FLT3, GPBAR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, HPGD, IGF1R, KDR, MET, NPSR1, PPARG, PTPRF, TSHR |
| CC | GO:0044456; synapse part | GO:0042734; presynaptic membrane | 8.443E-09 | 1.425E-06 | GRIK2, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 9.743E-09 | 1.595E-06 | GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 1.706E-08 | 2.579E-06 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 5.307E-08 | 7.360E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 8.618E-08 | 1.124E-05 | ABCG2, ACHE, AKT1, ALK, BCHE, BLM, CAMK2B, CSNK2A1, DAPK1, DRD4, ESR2, FLT3, GRIK2, GRIK5, HMGCR, HPGD, IGF1R, KDR, MAPK1, MAPT, MET, MMP9, NFKB1, PPARG, PYGL, SMN1, SMN2, STAT6, TP53, USP2, XDH |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.228E-07 | 1.520E-05 | AKT1, FFAR1, GRIK5, HIF1A, NOX4, NR1H4, PIK3R1, PPARG, PTPN2, PYGL |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.385E-07 | 2.705E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C8 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.987E-07 | 4.255E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 5.344E-07 | 5.515E-05 | ALK, CDK1, DRD4, GRM1, GRM4, MAPK1, PKN1, PLA2G1B, PTPN1 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 9.128E-07 | 8.913E-05 | ESR2, NR1H4, PPARA, PPARD, PPARG, RORC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.299E-07 | 9.000E-05 | CYP1A2, CYP2A6, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.299E-07 | 9.000E-05 | CYP1A2, CYP2C8, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 9.444E-07 | 9.099E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.097E-06 | 1.025E-04 | CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.109E-06 | 1.029E-04 | AKT1, HMGCR, MAPT, PTPN1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.186E-06 | 1.085E-04 | CYP1A2, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.521E-06 | 1.363E-04 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, BLM, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.772E-06 | 1.562E-04 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 2.285E-06 | 1.944E-04 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.784E-06 | 2.262E-04 | ESR2, NR1H4, PPARA, PPARD, PPARG, RORC |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.950E-06 | 2.336E-04 | CYP1A1, CYP2C8, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004556; alpha-amylase activity | 2.950E-06 | 2.336E-04 | AMY1A, AMY1B, AMY1C |
| MF | Unclassified; | GO:0103025; alpha-amylase activity (releasing maltohexaose) | 2.950E-06 | 2.336E-04 | AMY1A, AMY1B, AMY1C |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 3.342E-06 | 2.611E-04 | AKT1, CYP1B1, DAPK1, GRIK2, GRIK5, GSK3B, HMGCR, HPGD, MAPT, MMP9, NOX4, PPARG, PTPN2, SRC, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.348E-06 | 2.611E-04 | ALOX12, ALOX15, ALOX5, HPGD |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 5.870E-06 | 4.185E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.870E-06 | 4.185E-04 | CYP1A2, CYP2D6, CYP3A4 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 5.900E-06 | 4.185E-04 | AKR1B1, GRIK2, GRIK3, HIF1A, MAPK1, MAPT |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 6.570E-06 | 4.630E-04 | AKT1, HIF1A, LMNA, P4HB, PPARD, SRC, TP53 |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 7.010E-06 | 4.908E-04 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 7.454E-06 | 5.169E-04 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 9.738E-06 | 6.525E-04 | MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.022E-05 | 6.766E-04 | CYP1A1, CYP2A6, CYP2D6 |
| BP | GO:0032501; multicellular organismal process | GO:0007586; digestion | 1.054E-05 | 6.913E-04 | AKR1B10, ALPI, AMY1A, AMY1B, AMY1C, FABP2 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.073E-05 | 6.984E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.539E-05 | 9.768E-04 | MMP1, MMP13, MMP2, MMP3, MMP9, PLG |
| BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 1.922E-05 | 1.186E-03 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.221E-05 | 1.354E-03 | FABP2, FABP3, FABP4, FABP5 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.265E-05 | 1.374E-03 | AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 2.275E-05 | 1.376E-03 | AXL, CSNK2A1, DRD4, GSK3B, PPARA, PPARG, RORC, SRC, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 2.429E-05 | 1.453E-03 | BLM, RECQL, TP53 |
| MF | GO:0005488; binding | GO:0032052; bile acid binding | 2.429E-05 | 1.453E-03 | NR1H4, PLA2G1B, PYGL |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 2.456E-05 | 1.461E-03 | ESR2, NR1H4, PIM1, PPARA, PPARD, PPARG, RORC, SRC |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.504E-05 | 1.486E-03 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.581E-05 | 1.528E-03 | AKT1, BLM, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, PPARG, RORC, SRC |
| BP | GO:0032502; developmental process | GO:0007568; aging | 2.690E-05 | 1.588E-03 | AKT1, AURKB, CDK1, CYP1A1, HMGCR, MPO, NOX4, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 2.828E-05 | 1.664E-03 | ESR2, NR1H4, PPARA, PPARD, PPARG, RORC, SRC |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.453E-05 | 1.979E-03 | CA2, CA7, GRM5 |
| BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 3.453E-05 | 1.979E-03 | PPARG, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 3.538E-05 | 2.012E-03 | AKT1, FABP3, PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.495E-05 | 2.472E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 4.495E-05 | 2.472E-03 | ACHE, BCHE |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.495E-05 | 2.472E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0001641; group II metabotropic glutamate receptor activity | 4.495E-05 | 2.472E-03 | GRM2, GRM3 |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 5.250E-05 | 2.809E-03 | DRD4, PPARA, PPARG, RORC, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 5.353E-05 | 2.836E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 5.622E-05 | 2.957E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0008152; metabolic process | GO:0042446; hormone biosynthetic process | 5.622E-05 | 2.957E-03 | AKR1B1, CYP19A1, CYP3A4, HSD11B1, HSD17B2 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.086E-05 | 3.178E-03 | CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 6.890E-05 | 3.555E-03 | HIF1A, PPARA, PPARD, TP53 |
| BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 6.890E-05 | 3.555E-03 | AKT1, PPARA, PTPN2, SRC |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 7.640E-05 | 3.878E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 7.658E-05 | 3.878E-03 | AXL, F10, MET, NOX4, PIK3R1, PTK2, SRC |
| BP | GO:0065007; biological regulation | GO:0043281; regulation of cysteine-type endopeptidase activity involved in apoptotic process | 7.801E-05 | 3.941E-03 | AKT1, CSNK2A1, DAPK1, MAPT, MMP9, PPARG, SRC, XDH |
| BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 8.109E-05 | 4.078E-03 | PIK3R1, PTPN1, PTPN2 |
| MF | Unclassified; | GO:0032403; protein complex binding | 8.863E-05 | 4.396E-03 | ACHE, FLT3, IGF1R, KDR, MMP13, MMP9, P4HB, PIK3R1, PLG, PPARA, PTPN1, PTPN2, PTPRF, SRC, TLR2, TSHR |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 8.900E-05 | 4.404E-03 | AURKB, CA2, CA7, HIF1A, HMGCR, KDR, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B, SRC |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 1.008E-04 | 4.864E-03 | ABCG2, ACHE, AKT1, AXL, BLM, CAMK2B, FLT3, GRIK2, HIF1A, HMGCR, HPGD, MAPT, NFKB1, P4HB, PIK3R1, PPARD, PPARG, PYGL, TLR2, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0032872; regulation of stress-activated MAPK cascade | 1.051E-04 | 5.017E-03 | AKT1, GRIK2, HMGCR, IGF1R, MAPK1, PKN1, PTPN1, XDH |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.057E-04 | 5.034E-03 | CDK1, ESR2, NR1H4, PPARA, PPARD, PPARG, RORC |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.090E-04 | 5.152E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.246E-04 | 5.787E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.279E-04 | 5.899E-03 | GRIK2, GRIK3, GRIK5, MAPK1, SMN1, SMN2 |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 1.341E-04 | 6.015E-03 | CA3, CDK1, HMGCR, HPGD, POLB, TP53 |
| BP | Unclassified; | GO:0099566; regulation of postsynaptic cytosolic calcium ion concentration | 1.343E-04 | 6.015E-03 | GRM1, GRM5 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.343E-04 | 6.015E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.343E-04 | 6.015E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.343E-04 | 6.015E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.343E-04 | 6.015E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.343E-04 | 6.015E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.343E-04 | 6.015E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0099583; neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | 1.343E-04 | 6.015E-03 | GRM1, GRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.343E-04 | 6.015E-03 | GPBAR1, NR1H4 |
| CC | GO:0032991; macromolecular complex | GO:0032983; kainate selective glutamate receptor complex | 1.343E-04 | 6.015E-03 | GRIK2, GRIK5 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.611E-04 | 7.071E-03 | AXL, CDK1, CSNK2A1, FLT3, PPARG |
| CC | GO:0043226; organelle | GO:0070013; intracellular organelle lumen | 1.645E-04 | 7.176E-03 | ALOX5, BACE1, BCHE, CA5A, CA5B, CDK1, F10, FABP5, FLT3, GAA, GFER, HSD17B10, MAPK1, MMP9, MPO, NFKB1, P4HB, PLG, PYGL, TP53 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.713E-04 | 7.386E-03 | GRIK2, GRIK5, GSK3B, MAPT, TP53 |
| BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 1.890E-04 | 8.024E-03 | AKT1, CYP1B1, TLR2 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.890E-04 | 8.024E-03 | AURKB, MAPK1, NEK2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.890E-04 | 8.024E-03 | CYP1A1, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.890E-04 | 8.024E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0032501; multicellular organismal process | GO:0010634; positive regulation of epithelial cell migration | 2.018E-04 | 8.483E-03 | AKT1, HIF1A, KDR, MET, MMP9, SRC |
| BP | GO:0050896; response to stimulus | GO:1901654; response to ketone | 2.044E-04 | 8.561E-03 | AKR1B1, AKT1, CA9, CSNK2A1, PPARG, SRC, TLR2 |
| BP | GO:0008152; metabolic process | GO:0006694; steroid biosynthetic process | 2.107E-04 | 8.791E-03 | AKR1B1, CYP19A1, CYP3A4, HMGCR, HSD11B1, HSD17B2 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 2.159E-04 | 8.970E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 2.357E-04 | 9.575E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0051179; localization | GO:1900182; positive regulation of protein localization to nucleus | 2.496E-04 | 9.993E-03 | AKT1, CDK1, MAPK1, PIK3R1, SRC, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.112E-21 | 2.420E-17 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.299E-15 | 6.410E-12 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 1.891E-14 | 2.059E-11 | GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.940E-14 | 3.048E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.802E-21 | 1.360E-18 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 2.121E-14 | 2.121E-12 | GRIA2; GRIK5; SLC1A1; GRIK3; GRIK1; GRIK2; GRM1; GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRIA4 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.113E-11 | 3.057E-09 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 3.518E-11 | 2.345E-09 | GRIA2; GRIK5; GRIK3; GRIK1; PLG; GRIK2; TSHR; GRM1; GRM3; GRM2; GRM5; GRM4; ADORA3; GRM8; DRD4; GRIA4 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.637E-10 | 3.455E-08 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 7.793E-09 | 2.598E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.488E-08 | 6.977E-07 | GRM3; GRM2; GRM5; GRM4; CXCR1; GRM8; AKT1; MAPK1; PIK3R1; GRM1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.194E-08 | 1.463E-06 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; HMGCR; PYGL; CYP3A4; CYP19A1; HSD17B10; HSD11B1; FUT7; ALOX5; HSD17B2; XDH; AMY1A; GAA; AMY1B; AMY1C; CYP2C8; CYP2A6; AKR1B10; CYP1A2; ALDH1A1; CYP1A1; ALPI |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.697E-08 | 5.994E-07 | PTPN1; CSNK2A1; SRC; MAPK1; ACP1; MET; PTPRF; IGF1R |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.655E-08 | 5.994E-07 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.538E-08 | 4.393E-07 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 8.407E-08 | 1.463E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.675E-07 | 3.567E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; ESR2; GRM1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.781E-07 | 5.312E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.620E-07 | 3.567E-06 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.321E-07 | 5.312E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1; ESR2 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.510E-08 | 1.463E-06 | HSD11B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.622E-07 | 5.918E-06 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1; PTPRF |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.753E-07 | 5.312E-06 | HSD11B1; CYP2A6; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.370E-06 | 1.896E-05 | GSK3B; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; TLR2; IGF1R |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.844E-06 | 1.537E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.581E-06 | 1.375E-05 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 8.441E-07 | 8.441E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.057E-06 | 1.006E-05 | HSD11B1; CYP2C8; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.224E-06 | 3.890E-05 | CAMK2B; GRIA2; AKT1; MAPK1; PIK3R1; PPARA; NFKB1; TSHR; GRIA4 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.052E-06 | 2.794E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.782E-06 | 2.061E-05 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.919E-06 | 3.279E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 7.025E-06 | 4.133E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 8.570E-06 | 4.897E-05 | CYP2C8; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.805E-06 | 4.124E-05 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.052E-06 | 2.794E-05 | CYP2C8; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.208E-05 | 6.528E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.348E-05 | 6.913E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.757E-06 | 3.714E-05 | CYP2C8; CYP2A6; MAOA; CYP2D6; CYP1A2; CYP3A4 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.348E-05 | 6.913E-05 | ABCC1; ADORA3; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.158E-05 | 1.040E-04 | CAMK2B; GRIA2; GSK3B; MAOA; AKT1; DRD4; GRIA4 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.091E-05 | 1.338E-04 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.035E-05 | 1.338E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.629E-05 | 1.223E-04 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.137E-05 | 1.949E-04 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.491E-05 | 1.425E-04 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL; PTPRF |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.425E-05 | 1.425E-04 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 4.335E-05 | 1.734E-04 | CDK1; AKT1; MAPK1; PIK3R1; CDC25B; IGF1R |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.125E-06 | 1.023E-05 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.206E-04 | 3.938E-04 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 8.278E-05 | 2.905E-04 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.426E-04 | 4.457E-04 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1; CDC25B |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.185E-05 | 1.040E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.580E-04 | 1.053E-03 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.095E-04 | 9.237E-04 | LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.221E-04 | 3.938E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 3.912E-04 | 1.134E-03 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.065E-05 | 5.918E-05 | AMY1A; AMY1B; AMY1C; AKT1; PIK3R1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.651E-04 | 1.329E-03 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 3.145E-05 | 1.338E-04 | ALK; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.628E-05 | 8.141E-05 | GRM3; GRIA2; GRM2; MAOA; NFKB1 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 3.145E-05 | 1.338E-04 | AMY1A; AMY1B; GAA; AMY1C; PYGL |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.132E-04 | 3.775E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.986E-05 | 2.495E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 6.986E-05 | 2.495E-04 | CAMK2B; GRIA2; GRM5; MAPK1; GRM1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.132E-04 | 3.775E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 5.165E-05 | 1.949E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 6.986E-05 | 2.495E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 5.166E-04 | 1.435E-03 | GRIA2; GRM5; MAPK1; GRM1; GRIA4 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 5.906E-04 | 1.596E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.455E-04 | 7.552E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 7.938E-04 | 2.035E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.733E-04 | 8.281E-04 | GRM5; SRC; CDK1; MAPK1; GRM1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.004E-03 | 2.396E-03 | GSK3B; AKT1; MAPK1; PLG; PIK3R1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 5.906E-04 | 1.596E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 6.441E-04 | 1.673E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 9.918E-05 | 3.420E-04 | CA2; NR1H4; HMGCR; CYP3A4; ABCG2 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.095E-03 | 2.578E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1; TLR2 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.165E-05 | 1.949E-04 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.366E-03 | 5.200E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.085E-03 | 6.634E-03 | GSK3B; AKT1; PIK3R1; PPARA; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.366E-03 | 5.200E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.719E-03 | 3.908E-03 | AKT1; MAPK1; PPARG; PIK3R1; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.304E-03 | 3.033E-03 | AKT1; PPARG; PIK3R1; HMGCR; IGF1R |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.777E-03 | 3.994E-03 | AKT1; MAPK1; PIK3R1; GRM1; IGF1R |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.744E-03 | 7.800E-03 | PIM1; AKT1; STAT6; PIK3R1; PTPN2 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 6.493E-03 | 1.273E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1; CDC25B |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 6.862E-03 | 1.332E-02 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 7.245E-03 | 1.393E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.853E-03 | 9.610E-03 | BACE1; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.718E-02 | 4.315E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 8.298E-03 | 1.566E-02 | SRC; AKT1; MAPK1; PIK3R1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.595E-02 | 2.750E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.945E-03 | 6.401E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.978E-02 | 3.324E-02 | CAMK2B; SRC; MAPK1; PIK3R1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 3.844E-03 | 7.925E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 8.535E-03 | 1.580E-02 | CAMK2B; CDK1; MAPK1; IGF1R |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.280E-03 | 8.560E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 7.394E-03 | 1.408E-02 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 3.438E-03 | 7.238E-03 | CAMK2B; GRIA2; MAPK1; GRIA4 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 4.280E-03 | 8.560E-03 | CAMK2B; AKT1; PYGL; PPARA |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 4.131E-03 | 8.431E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.366E-02 | 3.817E-02 | ADORA3; AKT1; MAPK1; PIK3R1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 8.776E-03 | 1.596E-02 | GSK3B; CDK1; TP53; CDC25B |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 9.525E-03 | 1.716E-02 | GSK3B; MAPK1; MET; PTK2 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.677E-03 | 3.854E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.749E-02 | 4.329E-02 | CAMK2B; GSK3B; MAPK1 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.279E-02 | 3.718E-02 | AKT1; MAPK1; PIK3R1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.819E-04 | 1.357E-03 | FABP4; AKT1; PIK3R1; TSHR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 6.271E-04 | 1.650E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 2.092E-02 | 3.458E-02 | MMP1; MMP3; TLR2 |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 9.518E-04 | 2.337E-03 | CAMK2B; GRIA2; MAOA; GRIA4 |
| hsa04970 | Salivary secretion_Homo sapiens_hsa04970 | 2.032E-02 | 3.386E-02 | AMY1A; AMY1B; AMY1C |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 6.271E-04 | 1.650E-03 | GRIA2; MAPK1; GRM1; IGF1R |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.857E-02 | 3.147E-02 | MAPK1; PKN1; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 8.492E-04 | 2.150E-03 | RORC; STAT6; NFKB1; TLR2 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.006E-03 | 2.396E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.199E-02 | 2.085E-02 | MAPK1; NFKB1; TLR2 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 9.889E-03 | 1.750E-02 | AKT1; MAPK1; PIK3R1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.070E-02 | 1.877E-02 | AKT1; PPARA; NFKB1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 8.377E-03 | 1.566E-02 | AKT1; PIK3R1; IGF1R |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 8.741E-03 | 1.596E-02 | SRC; MAPK1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.299E-04 | 4.124E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.322E-03 | 7.067E-03 | CYP2A6; CYP3A4; XDH |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.656E-02 | 4.250E-02 | MAPK1; PIK3R1 |
| hsa05033 | Nicotine addiction_Homo sapiens_hsa05033 | 2.784E-02 | 4.350E-02 | GRIA2; GRIA4 |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.915E-02 | 4.519E-02 | FABP2; PLA2G1B |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 8.665E-04 | 2.166E-03 | MAPK1; PPARG; TP53 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 9.582E-04 | 2.337E-03 | AKR1B10; GAA; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.831E-02 | 3.130E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.287E-02 | 3.718E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 9.701E-03 | 1.732E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.658E-06 | 2.045E-05 | CYP2A6; CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Pulmonary embolism | I26 | PLG |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | PLG |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | HMGCR; PLG; PLG; PLG; MMP3 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| NA: NA | Dyslipidemia | NA | HMGCR; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | HMGCR; PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Autism | F84.0 | GRM5 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| NA: NA | GIST | NA | FLT3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| H60-H95: Diseases of the ear and mastoid process | Otitis media | H65-H67 | PLG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HMGCR; PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; MMP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; AKT1; FLT3; MMP2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; GRIA4; GRIA2; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; HMGCR; PLG; ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; GRM5; GRM2; PPARD |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; HMGCR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; HSD11B1; AKR1B1; PTPN1; FFAR1; GSK3B; PPARG |
| I00-I99: Diseases of the circulatory system | Chronic angina | I20 | PLG |
| NA: NA | Christmas disease | NA | F10 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| K00-K95: Diseases of the digestive system | Chemotherapy or radiotherapy-induced mucositis | K12.3, R52, G89 | HMGCR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP3; MMP2; MMP13 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRIK1; GRM1; ACHE; IGF1R; CDK1; MMP13 |
| NA: NA | Hyperlipidemia | NA | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HMGCR; PPARD |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HMGCR; KDR |
| NA: NA | Cardiovascular disease | NA | HMGCR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADORA3 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; GRM5; GRM3; GRM2; GRM4; CYP3A4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | GRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; PLG |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | GRM2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| NA: NA | Haemophilia B | NA | F10 |
| A00-B99: Certain infectious and parasitic diseases | HBV infection | B16, B18.0, B18.1 | HMGCR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; FLT3 |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10 |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; FLT3; CA9; IGF1R; CYP19A1; CDK1; KDR; KDR; KDR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| NA: NA | Heart attack | NA | PLG |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10 |
| NA: NA | Acute coronary thrombosis | NA | PLG |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; FFAR1; NFKB1; PPARG; PPARG; GPBAR1; PPARD |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; TLR2; AKT1; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Fragile X syndrome | F02.3, G20, Q99.2 | GRM5 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; GRIK1; GRM1; GRM5 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; GRM3; GRM2; DRD4 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HMGCR; SRC; IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; HMGCR; ALOX5; PPARD |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; MMP3; MMP1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; GRM5; GRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Chronic neuropathic pain | G64, G90.0, K21, R52, G89 | GRM5; GRM5 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Excessive postoperative bleeding | R58 | PLG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| C00-D49: Neoplasms | Renal cancer | C64 | F10; CA9; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10 |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; HMGCR; ALOX5 |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| NA: NA | GERD | NA | GRM5 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; GRM5; GRM5; GRM3; GRM2; GRM2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; GRM5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | PLG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; GRIK1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRIK1; GRM1; NPSR1; GRM5; GRM4 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | PLG; MMP3 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Excessive bleeding | R58 | PLG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Elevated CRP | E78.0 | HMGCR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; FFAR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; AXL; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; PPARG; PPARD; PPARD |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; GRIK1; GRIK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; PLG; GRM1; ACHE; ACHE; ACHE; GSK3B; PPARG; PPARG; GRM5; GRM3; GRM2 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MET; TLR2; CSNK2A1; AKT1; PLG; CA1; FLT3; FLT3; CA9; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; CDC25B; TP53; KDR |